Nathan A Lack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1148778/publications.pdf Version: 2024-02-01



NATHAN ALACK

#	Article	IF	CITATIONS
1	Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening Journal of Medicinal Chemistry, 2011, 54, 8563-8573.	6.4	136
2	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	16.8	127
3	Inhibitors of Androgen Receptor Activation Function-2 (AF2) Site Identified through Virtual Screening. Journal of Medicinal Chemistry, 2011, 54, 6197-6205.	6.4	85
4	Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1 <i>H</i> -benzimidazole Derivatives. Journal of Medicinal Chemistry, 2013, 56, 1136-1148.	6.4	81
5	Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nature Cell Biology, 2022, 24, 554-564.	10.3	53
6	Androgen receptor-binding sites are highly mutated in prostate cancer. Nature Communications, 2020, 11, 832.	12.8	44
7	Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 1235-1241.	3.0	39
8	Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. Oncogene, 2020, 39, 2187-2201.	5.9	28
9	New Therapeutics to Treat Castrate-Resistant Prostate Cancer. Scientific World Journal, The, 2013, 2013, 1-8.	2.1	22
10	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discovery, 2022, 12, 2074-2097.	9.4	22
11	DeepCOP: deep learning-based approach to predict gene regulating effects of small molecules. Bioinformatics, 2020, 36, 813-818.	4.1	21
12	Functional mapping of androgen receptor enhancer activity. Genome Biology, 2021, 22, 149.	8.8	18
13	Determining the origin of synchronous multifocal bladder cancer by exome sequencing. BMC Cancer, 2015, 15, 871.	2.6	17
14	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	4.1	16
15	Androgen Receptor-Mediated Transcription in Prostate Cancer. Cells, 2022, 11, 898.	4.1	14
16	Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 14968-14982.	6.4	9
17	DNA binding alters ARv7 dimer interactions. Journal of Cell Science, 2021, 134, .	2.0	7
18	Histologically benign Plâ€RADS 4 and 5 lesions contain cancerâ€associated epigenetic alterations. Prostate, 2022, 82, 145-153.	2.3	0